Use of Insulin Adjustment Device DreaMed Advisor Pro During Routine Clinical Use for Subjects With Diabetes Type 1
Condition: Type 1 Diabetes Intervention: Device: DreaMed Advisor Pro Sponsor: Rabin Medical Center Not yet recruiting
This article aims for summarizing current clinical knowledge on screening, diagnosis, and treatment and gives an overview on the pathophysiology of exocrine pancreatic insufficiency in diabetes.Recent FindingsRecent studies reveal novel insights into the close interaction of acinar, ductal, and endocrine cells and the gut-pancreas axis.SummaryExocrine pancreatic insufficiency is a clinically relevant, frequent but poorly understood disorder in both type 1 and type 2 diabetes.
Publication date: April 2020Source: Canadian Journal of Diabetes, Volume 44, Issue 3Author(s): Ilia Ostrovski, Leif E. Lovblom, Daniel Scarr, Alanna Weisman, Nancy Cardinez, Andrej Orszag, C. Marcelo Falappa, Émilie D'Aoust, Ahmad Haidar, Rémi Rabasa-Lhoret, Laurent Legault, Bruce A. Perkins
ConclusionsContinuous glucose monitoring device helped in the management of diabetes, although more research is needed to analyse the influence of other variables in the relations studied.
CONCLUSION: Proper insulin dosing based on carbohydrate counting (CC) may have an impact on the antioxidant defensive mechanisms of patients with T1DM through the attainment of a better glycemic profile. There are also indications that it may reduce MDA, an important biomarker of oxidative stress and a significant mediator of complications in T1DM. Therefore, prompt dietetic intervention using CC as early as possible after the diagnosis of T1DM is important for achieving optimal glycemic control and improved oxidative status. PMID: 32221838 [PubMed - as supplied by publisher]
TUESDAY, March 31, 2020 -- Real-world data support the benefit of using the Medtronic MiniMed 670G insulin pump system for glycemic control in type 1 diabetes, according to a study presented at the virtual meeting of The Endocrine Society, held from...
Type 1 diabetes mellitus (T1DM) is the most common form of diabetes mellitus in the pediatric population, with an estimated 500,000 children living with T1DM and an estimated 80,000 new cases each year in the United States. Ophthalmologic complications of diabetes are common in adult patients and those with longstanding disease, but can also be seen in patients with a recent diagnosis, even among the pediatric population.
AbstractProteinuria has been considered to be the hallmark of diabetic kidney disease and to precede renal function loss. However, it has become clear that a substantial proportion of patients either with type 1 diabetes or type 2 diabetes have renal function loss without proteinuria, known as nonproteinuric diabetic kidney disease. Despite increasing recognition of the prevalence of nonproteinuric diabetic kidney disease, data on this phenotype of diabetic kidney disease is sparse. This review describes ever known clinical and pathological manifestations, renal prognosis, and mortality in patient with nonproteinuric diabetic kidney disease.
(St. Jude Children's Research Hospital) Scientists at St. Jude Children's Research Hospital mapped the epigenetic controls on T cells, which could aid Type 1 diabetes diagnosis and treatment, as well as cancer immunotherapy.
Type 1 diabetes mellitus (T1DM) prevalence is increasing and despite all available modern treatment options, an overall small but noticeable increase of mean HbA1c was recently observed in various registries. Authorized adjunctive pharmacological treatment options to insulin therapy are still scarce for T1DM. In February 2019, the European Medicines Agency (EMA) approved dapagliflozin as the first in class sodium/glucose co-transporter 2 inhibitor (SGLT-2i) adjunctive therapy to insulin in patients with T1DM, which is currently still not approved by the FDA in the United States.
In this study, we aimed to evaluate the influence of insulin production on immune system after the onset of diabetes, and we showed that the duration of honeymoon period could be related to the onset of other autoimmune conditions. For this retrospective study, 159 children aged between 11 and 18 years with type 1 DM were eligible. They have been diagnosed diabetes at least 10 years ago and use exogenous insulin. Our results showed that younger age at the onset of Type 1 DM in children, predicts Celiac Disease. Female sex and low HCO3 levels at the onset of DM had a high predictive value on patients who did not experience ...